Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.37 |
| ▸ | SCN1A | P35498 | 3/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | THPO | P40225 | 3/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969950 | 0.82 | NSD2 (0.38) | NSD2CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2967022 | 0.79 | TP53BP1 (0.40) | NSD2ALDH1A1TP53NPSR1MAPT | |
| SCHEMBL2971174 | 0.76 | KDM4E (0.38) | CYP3A4CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2976173 | 0.76 | USP30 (0.42) | CYP3A4CYP2C9TP53CYP2D6MEN1 | |
| SCHEMBL2978850 | 0.74 | NSD2 (0.49) | NSD2ALDH1A1KDM4EMAPK1MEN1 | |
| SCHEMBL6108893 | 0.68 | EPAS1 (0.50) | ALDH1A1KDM4EHSD17B10MAPTSYK | |
| SCHEMBL13203007 | 0.65 | SYK (0.50) | SYK | |
| SCHEMBL5241227 | 0.64 | NSD2 (0.49) | NSD2ALDH1A1KDM4EMAPK1MEN1 | |
| SCHEMBL2968069 | 0.63 | TP53BP1 (0.40) | ALDH1A1TP53MEN1KMT2ANPSR1 | |
| SCHEMBL21878809 | 0.62 | NSD2 (1.00) | NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | claimed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7605144-B2 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| EP-1200455-B1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | CELMED ONCOLOGY USA INC (CA) | 2009-04-22 | — | — | EP | disclosed |
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | CELMED ONCOLOGY (USA), INC. | 2009-03-12 | — | — | US | disclosed |
| US-7462605-B2 | Phosphoramidate compounds and methods of use | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-09 | — | — | US | disclosed |
| US-7419968-B1 | Methods for treating therapy-resistant tumors | CELMED ONCOLOGY (USA), INC. (CA) | 2008-09-02 | — | — | US | disclosed |
| US-20020151519-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. (CA) | 2002-10-17 | — | — | US | disclosed |
| US-20020147175-A1 | Synergistic ECTA compositions | NEWBIOTICS, INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002056832-A2 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NEWBIOTICS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002039952-A2 | SYNERGISTIC ECTA COMPOSITIONS | NEWBIOTICS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1202749-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | Newbiotics, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1200130-A2 | METHODS FOR TREATING THERAPY-RESISTANT TUMORS | Newbiotics, Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1200455-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | Newbiotics Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001007087-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007454-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007088-A2 | METHODS FOR TREATING THERAPY-RESISTANT TUMORS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | MTAP, TYMP, INPP5D | NSD2 2454/4885CYP3A4 4162/4885CYP1A2 4837/4885 |
| US-20020147175-A1 | Synergistic ECTA compositions | ENTPD1, ENTPD2, ENPP1 | NSD2 4517/4885CYP3A4 4847/4885CYP1A2 4243/4885 |
| US-20020151519-A1 | Methods to treat autoimmune and inflammatory conditions | SSB, ENPP2, TPMT | NSD2 3990/4885CYP3A4 3415/4885CYP1A2 2232/4885 |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | NSD2 1687/4885CYP3A4 708/4885CYP1A2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.